Semaglutide
US$ 27.02
semaglutide and cardiovascular outcomes in obesity without diabetes Wegovy lowers cardiovascular risk for
Description
The booming GLP-1 market, projected to reach $167bn by 2031, presents compelling opportunities for private equity players to carve out their niche and capture substantial value, despite industry giants Novo Nordisk and Eli Lilly dominating the lions share of the market. Download PDF
Randomized controlled trials (RCTs) comparing insulin with established GLP-1 RAs, DPP-4is, or SGLT-2is were included
Explore GLP-1 SEMA 10MG peptide for research purposes
Novo-Nordisk A/S, Eli Lilly And Company, Sanofi, AstraZeneca, Pfizer Inc., Amgen, Inc., and Innovent Biologics, Inc
